NCT02705534View on ClinicalTrials.gov

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2017

Conditions
Hepatitis CCirrhosis
Interventions
DRUG

Sofosbuvir

400 mg, included in a combination pill with 90 mg ledipasvir

DRUG

Ledipasvir

90 mg, included in a combination pill with 400 mg sofosbuvir

DRUG

Ribavirin

1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses

Trial Locations (1)

14117

Shariati Hospital, Tehran

All Listed Sponsors
collaborator

Bakhtar Bioshimi Co

UNKNOWN

lead

Tehran University of Medical Sciences

OTHER

NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 | Biotech Hunter | Biotech Hunter